Patents by Inventor Jan Stracke

Jan Stracke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for the purification of an N-terminal fragment of hepatocyte growth factor
    Patent number: 7544493
    Abstract: A method for the production of the N-terminal four kringle-containing fragment of hepatocyte growth factor (NK4) by expression of a nucleic acid encoding said NK4 in a microbial host cell, isolation of inclusion bodies containing said NK4 in denatured form, solubilization of the inclusion bodies and naturation of the denatured NK4, characterized in that solubilization and naturation are performed at pH 7-9 in phosphate buffered solution, provides NK4 in high purity and high yield.
    Type: Grant
    Filed: March 2, 2005
    Date of Patent: June 9, 2009
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Friederike Hesse, Martin Lanzendoerfer, Apollon Papadimitriou, Jan Stracke
  • Method for the Purification of an N-Terminal Fragment of Hepatocyte Growth Factor
    Publication number: 20070287827
    Abstract: A method for the production of the N-terminal four kringle-containing fragment of hepatocyte growth factor (NK4) by expression of a nucleic acid encoding said NK4 in a microbial host cell, isolation of inclusion bodies containing said NK4 in denatured form, solubilization of the inclusion bodies and naturation of the denatured NK4, characterized in that solubilization and naturation are performed at pH 7-9 in phosphate buffered solution, provides NK4 in high purity and high yield.
    Type: Application
    Filed: March 2, 2005
    Publication date: December 13, 2007
    Inventors: Friederike Hesse, Martin Lanzendoerfer, Apollon Papadimitriou, Jan Stracke
  • Antibodies against IL-13 receptor alpha1 and uses thereof
    Publication number: 20060263356
    Abstract: An antibody binding to IL-13R?1, inhibiting IL-13 bioactivity and comprising a variable heavy and a variable light chain, characterized in that the variable heavy chain amino acid sequence CDR3 of said antibody is selected from the group consisting of the heavy chain CDR3 sequences of SEQ ID NO: 1, 3, 5, 7 or 9 is useful in the treatment of asthma and allergic diseases.
    Type: Application
    Filed: January 3, 2006
    Publication date: November 23, 2006
    Inventors: Josef Endl, Maria Fuentes, Yvo Graus, Adelbert Grossmann, Sebastian Neumann, Paul Parren, Frank Rebers, Joerg Regula, Ralf Schumacher, Stefan Seeber, Jan stracke, Kay-Gunnar Stubenrauch, Jan Van De Winkel, Martine Van Vugt, Sandra Vereecken-Verploegen